We investigate the influence of the source’s energy fluctuation on both computational ghost imaging and computational ghost imaging via sparsity constraint,and if the reconstruction quality will decrease with the inc...We investigate the influence of the source’s energy fluctuation on both computational ghost imaging and computational ghost imaging via sparsity constraint,and if the reconstruction quality will decrease with the increase of the source’s energy fluctuation.In order to overcome the problem of image degradation,a correction approach against the source’s energy fluctuation is proposed by recording the source’s fluctuation with a monitor before modulation and correcting the echo signal or the intensity of computed reference light field with the data recorded by the monitor.Both the numerical simulation and experimental results demonstrate that computational ghost imaging via sparsity constraint can be enhanced by correcting the echo signal or the intensity of computed reference light field,while only correcting the echo signal is valid for computational ghost imaging.展开更多
Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit ...Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We conducted a randomized,controlled,open-label multicenter trial among COVID-19 patients.The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone.The cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were observed.Thirty-three patients were randomized to the tocilizumab group,and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events occurred.More mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative.For patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome.展开更多
基金supported by the Youth Innovation Promotion Association of the Chinese Academy of Sciences,the Defense Industrial Technology Development Program of China(No.D040301)the National Natural Science Foundation of China(No.61571427)the Civil Aerospace Pre-research Project(No.D020214)。
文摘We investigate the influence of the source’s energy fluctuation on both computational ghost imaging and computational ghost imaging via sparsity constraint,and if the reconstruction quality will decrease with the increase of the source’s energy fluctuation.In order to overcome the problem of image degradation,a correction approach against the source’s energy fluctuation is proposed by recording the source’s fluctuation with a monitor before modulation and correcting the echo signal or the intensity of computed reference light field with the data recorded by the monitor.Both the numerical simulation and experimental results demonstrate that computational ghost imaging via sparsity constraint can be enhanced by correcting the echo signal or the intensity of computed reference light field,while only correcting the echo signal is valid for computational ghost imaging.
基金This work was supported by the Department of Science and Technology of Anhui Province and Health Commission of Anhui Province(No.202004a07020001)the China National Center for Biotechnology Development(No.2020YFC0843800).
文摘Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We conducted a randomized,controlled,open-label multicenter trial among COVID-19 patients.The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone.The cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were observed.Thirty-three patients were randomized to the tocilizumab group,and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events occurred.More mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative.For patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome.
